Background We performed a retrospective study of our patients with spondyloarthritis (SpA) in biologic therapy admitted to hospital over the past 14 years.
Methods Patients with SpA attending clinics at the Department of Rheumatology were analyzed to determine how many of them required hospitalization from January 1999 until December 2012. We recorded: age, sex, duration of disease, type of SpA, number and reasons for admission, and its outcome.
Results A total of 139 patients were identified from an electronic database, 61 were admitted to hospital at least once, mean age at admission 45.9 years, 44 male. We obtained 74 hospitalizations over 14 years. Mortality rate: 3,2%. Readmission rate: 18%. Type of SpA: 37.7% axial spondyloarthritis, 39,3% peripheral spondyloarthritis, 23% mixed type of disease. Anti-TNF: Etanercept 28 patients, infliximab 16 patients, adalimumab 10 patients. Reasons for admission in order of frequency:
Orthopedic surgery (17 cases).
General surgery (15).
Cardiac diseases (7).
Obstetric Pathology (5)
Respiratory disease (4)
Among the most serious diseases we found an acute liver failure which needed liver transplantation, a miliary tuberculosis, and a severe interstitial lung disease that caused the patient’s death three months after diagnosis.
Conclusions In our cohort, 43.8 % of patients required hospitalization, the reasons for admission were basically orthopedic surgery followed by general surgery. Despite immunosuppressive state caused by TNF blockers, there were only a few cases of infection, although two of these cases were life-threatening. The spondyloarthritis are still among diseases with serious medical, social and economic involvements.
Disclosure of Interest None Declared